CTOs on the Move

Hill, Barth and King LLC

www.hbkcpa.com

 
Established in 1949, HBK serves over ten thousand clients - ranging from individuals to small businesses to multimillion-dollar corporations - across the United States.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.hbkcpa.com
  • 25 E Boardman St
    Youngstown, OH USA 44503-1843
  • Phone: 330.747.1903

Executives

Name Title Contact Details

Similar Companies

Achieve Productions

Achieve Productions is a Scarsdale, NY-based company in the Business Services sector.

CVPartners

CVPartners is a Mountain View, CA-based company in the Business Services sector.

Airstar Space Lighting USA

Airstar Space Lighting USA is a Austin, TX-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN